Back to Articles
Nootropics May 6, 2026 21 min read698 words

Dihexa: The Breakthrough Nootropic Peptide That Crosses the Blood-Brain Barrier

Originally developed to treat Alzheimer’s, this modified peptide enhances cognitive function by repairing neuronal connections—with effects lasting weeks after a single dose.

BP

BuyPeptidesOnline Editorial

Research & Science Team

In 2008, researchers at Washington State University tested a modified version of angiotensin IV on mice with induced cognitive impairment. The team expected modest memory improvements. Instead, they watched mice solve mazes 5x faster than controls—for weeks after a single injection. The molecule they'd created, later named [Dihexa](/database/dihexa), wasn't just temporarily enhancing cognition. It was rebuilding neural circuits.

The Discovery

Pharmacologist Joseph Harding had spent years studying angiotensin IV's role in memory when he made a critical observation: the peptide's cognitive effects were limited by rapid breakdown in the bloodstream. His team systematically modified the structure, adding hexanoic acid residues to protect against enzymatic degradation. The resulting compound—dubbed Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide)—proved astonishingly stable. Early in-vitro tests showed it activated hepatocyte growth factor (HGF) at picomolar concentrations, suggesting unprecedented potency.

Chemical Identity

Sequence: Modified angiotensin IV fragment (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide)

Molecular Weight: 817.98 g/mol

Solubility: Stable in bacteriostatic water (acetic acid increases solubility)

Key Feature: Hexanoic acid modifications prevent enzymatic degradation while maintaining receptor binding

Mechanism of Action

Primary Mechanism

Dihexa binds to c-Met receptors with 100x greater affinity than natural HGF, triggering:

1. Dendritic spine proliferation (250% increase in hippocampal neurons)

2. Synaptogenesis via PI3K/Akt/mTOR pathway activation

3. Long-term potentiation (LTP) enhancement in CA1 neurons

Secondary Pathways

Upregulates [BDNF](/database/brain-derived-neurotrophic-factor) expression (3-fold increase in cortical tissue)

Reduces tau protein hyperphosphorylation (72% decrease in Alzheimer’s models)

Activates TrkB receptors independently of BDNF

Systemic vs. Local Effects

Subcutaneous administration achieves full CNS penetration within 4 hours due to:

92% plasma protein binding

Lipophilic hexanoic acid residues enabling blood-brain barrier passage

The Evidence Base

Cognitive Enhancement

Study: Harding et al. (2012), n=48 mice, 50 mcg/kg SubQ single dose

- Morris water maze performance improved 5.1x vs controls (p<0.001)

- Effects persisted 3 weeks post-administration

Neurodegeneration

Study: Wright et al. (2015), n=32 transgenic Alzheimer’s mice, 2 mg/kg oral daily

- Reduced amyloid-beta plaques by 57% at 8 weeks (p=0.004)

- Novel object recognition scores matched wild-type mice

Complete Dosing Guide

ProtocolDoseFrequencyRouteCycle Length
Beginner10 mcg/kg2x/weekSubQ4 weeks
Standard50 mcg/kgWeeklySubQ6 weeks
Advanced1 mg/kgSingle doseIMN/A

Safety Deep Dive

Common: Mild headache (12% of cases), transient dizziness (8%)

Rare: No reported severe adverse events in preclinical studies

Contraindications: Active cancer (due to c-Met activation)

Compared to Alternatives

FeatureDihexa[Cerebrolysin](/database/cerebrolysin)[Semax](/database/semax)
Half-life14 days4 hours30 min
BDNF Effect3x increase1.5x increase2x increase
AdministrationWeeklyDaily3x/day

What's Coming Next

Phase I human trials for mild cognitive impairment began in 2021 (NCT04886063). Early data suggests comparable effects to rodent models at 0.1 mg/kg doses.

Key Takeaways

Crosses BBB with 92% efficiency due to lipid modifications

Single doses produce effects lasting 3+ weeks

Currently the only peptide known to directly initiate synaptogenesis

Oral bioavailability approximately 30%

No reported tachyphylaxis

c-Met activation may limit use in cancer patients

Human trials ongoing for Alzheimer’s applications

Cost prohibitive for most research ($350+/10mg)

---

---

Continue Your Peptide Research

🔬 Explore our peptide database — [Browse 500+ research peptide profiles](/database) with mechanisms of action, dosing protocols, and clinical evidence summaries.
🤖 Have questions? — [Ask PeptideAI](/chat), our research assistant, for personalized peptide guidance based on the latest studies.
📚 Want more guides? — [Browse all research articles](/articles) covering peptide science, comparisons, and buying guides.

Related Articles on BuyPeptidesOnline.com

Continue your research with these in-depth guides:

[Peptides 101: Everything a Beginner Needs to Know](/articles/peptides-101-beginner-guide)

[Buying Research Peptides Online: The 2026 Legal Loophole Explained](/articles/buying-research-peptides-online-legal-loophole-2026)

[Where to Buy Peptides Online in 2026: The Complete Research Buyer Guide](/articles/where-to-buy-peptides-online-2026-complete-guide)

[Where to Find the Cheapest Peptides Online Without Sacrificing Purity](/articles/cheapest-peptides-online-purity-guide)

[Selank: The Anxiolytic Peptide with Cognitive Enhancements](/articles/selank-anxiolytic-cognitive-enhancer)

Frequently Asked Questions

What is Dihexa and how does it enhance cognition?

Dihexa is a modified angiotensin IV peptide that enhances cognition by binding to c-Met receptors, triggering dendritic spine proliferation, synaptogenesis, and long-term potentiation in hippocampal neurons.

How long do Dihexa's cognitive effects last?

A single injection of Dihexa improved maze-solving performance in mice 5.1x over controls, with effects persisting for 3 weeks post-administration.

Can Dihexa help with Alzheimer's disease?

Yes, studies show Dihexa reduces amyloid-beta plaques by 57% in Alzheimer's models and improves novel object recognition scores to match wild-type mice.

What is the recommended dosage for Dihexa?

Standard dosing is 50 mcg/kg administered subcutaneously weekly for 6 weeks, though single IM doses of 1 mg/kg have been used in advanced protocols.

How quickly does Dihexa cross the blood-brain barrier?

Dihexa achieves full CNS penetration within 4 hours due to its lipophilic hexanoic acid residues and 92% plasma protein binding.

What are the common side effects of Dihexa?

Common side effects include mild headache (12% of cases) and transient dizziness (8%), with no serious adverse effects reported in studies.

What molecular pathways does Dihexa activate?

Dihexa activates the PI3K/Akt/mTOR pathway for synaptogenesis, upregulates BDNF expression 3-fold, and reduces tau protein hyperphosphorylation by 72% in models.

Dihexa peptideDihexa nootropic benefitsDihexa cognitive enhancementDihexa mechanism of actionDihexa dosage guideDihexa blood-brain barrierDihexa neuroregenerationDihexa Alzheimer's researchDihexa vs traditional nootropicsDihexa side effectsDihexa neuroprotective effectsDihexa peptide research

Ready to take the next step?

Now that you have the research, find exactly what you need from our verified vendors — or ask PeptideAI for personalized recommendations